RNAi-siRNAI-miRNA-shRNA News: Breaking RNAi-siRNAI-miRNA-shRNA News, Comments and Articles. - Page: 2

EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2

MicroRNAs (miRNAs) are generated by two-step processing to yield small RNAs that negatively regulate target gene expression at the post-transcriptional level. Deregulation of miRNAs has been linked to diverse pathological processes, including cancer....

Learn molecular biology from renowned professors and industry leaders at the 2013 Smith College Molecular Biology Summer Workshops, sponsored by New England Biolabs

IPSWICH, Mass. and NORTHAMPTON, Mass., May 1, 2013 /PRNewswire/ -- This summer, Smith College is hosting the 28th annual Molecular Biology Summer Workshops at the Ford Science Center in Northampton, MA.  In cooperation with New England Biolabs (NEB), a leader in the research and development of reagents for the life sciences, Smith College invites interested parties to learn molecular biology...

Announcement - Clontech Laboratories, Inc. Releases the SMARTer® Universal Low Input RNA Kit for Sequencing

MOUNTAIN VIEW, Calif., May 1, 2013 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the SMARTer Universal Low Input RNA Kit for Sequencing. The SMARTer Universal Low Input RNA Kit extends Clontech's NGS (Next Generation Sequencing) solutions to include low input samples of compromised RNA. It combines Clontech's patented SMAR...

RXi Pharmaceuticals to Present at the 2013 ARVO Annual Meeting

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company will be presenting an overview of the use of sd-rxRNAs® in the eye and highlighting specifically RXi’s work...

SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board

JUPITER, Fla., April 30, 2013 /PRNewswire/ -- SMaRT Therapeutics, Inc., a leading biotechnology company focused on the development of small-molecule drugs that target and modulate RNA, announced the appointment of Dr. John H. Abeles to its Advisory Board.  Dr. Abeles has had a long and distinguished career in the biotechnology and pharmaceutical industries.  He practiced medicine...

Ascletis Gains China Market Rights from Janssen to a Clinical Stage HIV Protease Inhibitor

HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013 /PRNewswire/ -- Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in Greater China, includi...

Arrowhead Prices $36 Million Private Offering

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has priced a private offering with gross proceeds expected to be $36 million. The offering was priced at $1.83 per common share. Approximately 14.3 million shares of common stock and 9,900 shares of series B convertible preferred stock are expec...

Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter ending March 31, 2013 on Monday, May 6, 2013, after the U.S. financial markets close. Management will provide an update on the company, discuss first quarter results, and discuss expe...

RXi Pharmaceuticals Announces Investor and Analyst Symposium

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it will hold its first Investor and Analyst Symposium. During this meeting, the company Management and members of...

Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation

Arrowhead to Present at Master Investor 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its President and CEO, Dr. Chris Anzalone, will present at Master Investor, the UK’s leading investment show, on Saturday, April 27 at 2:05 p.m. BST at the Business Design Centre in London. Details can be found on the event website at http://masterinvestor.co.uk...

Arrowhead to Present at Needham Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its COO and Head of R&D, Dr. Bruce Given, will present at the Needham Healthcare Conference on Tuesday, April 30 at 8:40 a.m. Eastern time at the Westin Grand Central Hotel in New York City. A live webcast of the presentation can be accessed by...

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity

Alnylam to Webcast Presentation at 12th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 3:40 p.m. ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be av...

Asuragen Announces Publication on Standardization of BCR-ABL1 Testing on the International Scale

Asuragen, Inc. announced today that the results of an international, multi-center validation study on its ARQ IS Calibrator Panels* have been published online and will appear in Clinical Chemistry. The study, performed in collaboration with clinical laboratories in Australia, Canada, Brazil, Germany, Italy, Korea, Spain, the UK and the USA, shows th...

The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy

ByPropThink: By Jake King Tekmira's (TKMR) story over the last few years has largely been focused on its siRNA delivery technology, lipid nanoparticles (LNPs), and the ability of the platform to be used in broader RNAi applications. But the focus of investors is shifting as Tekmira brings a new therapy into the clinic this year and moves out of early-stage clinical development and into proof-of-...

RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that H. Paul Dorman and Curtis Lockshin, Ph.D. have been appointed to the Company’s Board of Directors. Mr. Dorman and Dr. Lo...

[UWA] licenses exon-skipping drug IP to [AVI BioPharma]

RNAI therapeutics developer [AVI BioPharma Inc.] has received exclusive worldwide rights to the [University of Western Australia]’s patent application, “Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof,” which th...

Series D round brings $15mm to [Asuragen]

[Asuragen Inc.] (mRNA- and miRNA-based molecular diagnostics for cancer and genetic diseases) raised $15mm from 15 undisclosed investors in what appears to be the company's Series D round.

Genable Technologies secures Orphan Drug Designation for gene therapy product

Genable Technologies’ gene therapy product, GT038, has been granted Orphan Drug Designation by the FDA for the treatment of retinitis pigmentosa. This will provide the company with seven years market exclusivity once GT308 has secured regulatory ap...

Percepta Survey Finds Personnel, Reagent and Instrument Spending in Academic Research Labs Negatively Affected Both Prior to and Post Budget Sequester

Though the U.S. Federal government implemented budget sequestration on March 1st, canceling $85 billion in budgetary resources across the Federal government for the remainder of the 2013 fiscal year, U.S. academic researchers spending on life science reagents and instruments decreased as early as October 2012, according to Percepta’s recent benchmarking...

HCV clinical trial application submitted to Recombinant DNA Advisory Committee (RAC)

SYDNEY, April 16, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee (RAC) . The RAC submission document comprises the full clinical trial protocol for its fir...

Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimer's Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting

NEW YORK, April 16, 2013 /PRNewswire/ -- Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV me...

Veritas Bio’s RNA Delivery Patent Allowed by USPTO

Veritas Bio, LLC, a privately held biotechnology company is pleased to announce that it has received a Notice of Allowance from the USPTO for Patent Application No. 12/514,237, “In Vivo Delivery Of Double Stranded RNA To a Target Cell”. Dr. Pachuk, the inventor said, “The allowed claims cover transfecting double-stranded RNA into skin or mus...

Ascletis and Roche to Develop Hepatitis C Treatment for China

Ascletis, a two-year-old China pharma startup, will collaborate with Roche to develop a Roche drug candidate for treatment of hepatitis C virus in China. Danoprevir is a protease inhibitor that has shown efficacy in European Phase II tests against HC...